Immutep

IMMUFACT

image Immutep S.A. announces that IMMUFACT® IMP321 has successfully completed Phase I Studies.

Immutep S.A. announced today that its lead product, ImmuFact® IMP321, has successfully completed two large randomised Phase I clinical studies assessing safety, tolerability and immune response in normal healthy volunteers. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response in therapeutic vaccines.

Click to read the complete Press Release (PDF Format).


Published 05/2006 by admin@immutep.com
» Office and Laboratory Leases
© 2002 Immutep, S.A.
Press Release
10/2008 - IMP321 IND Allowance in Pancreatic Cancer
image Immutep S.A. announced today that the FDA, after review of the ...
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy
image Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer
image Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients
image Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I
image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...